Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Paracetamol + chlorpheniramine maleate + phenylephrine is an approved oral small-molecule combination drug used to treat symptoms of the common cold, influenza, and allergic rhinitis, including nasal congestion, fever, headache, body aches, and sinus pressure. It contains three active ingredients: paracetamol (acetaminophen), an analgesic and antipyretic that inhibits prostaglandin synthesis in the central nervous system to relieve pain and reduce fever; phenylephrine, a sympathomimetic decongestant that stimulates alpha-1 adrenergic receptors to constrict blood vessels in the nasal mucosa, thereby relieving nasal congestion and sinus pressure; and chlorpheniramine maleate, a first-generation antihistamine that blocks H1 histamine receptors to alleviate allergy symptoms such as sneezing, runny nose, watery eyes, and itching.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on paracetamol + chlorpheniramine maleate + phenylephrine.